Commercial Prior Authorization Requirements List

Services Requiring Prior Authorization (Revised May 2025)

Please note: The terms prior authorization, prior approval, predetermination, advance notice, precertification, preauthorization and prior notification all refer to the same process.

CATEGORY	DETAILS	SUBMIT TO (PROVIDER USE ONLY)
Outpatient Services **(Furnished in a physician office, certified ambulatory surgery center, outpatient hospital, or any other location)**	Ambulance services DME Gene Expression/Microarray Analysis Other Medical/Surgical/Diagnostic Services Reconstructive procedures Surgical Procedure Other additional services **Please go to HERE for a list of codes that require prior authorization.**	Care Management Web: https://login.coherehealth.com **All contracted providers need to submit via the web. Only non-contracted providers can submit via fax.** Fax: 1-877-321-6664 or Prior Approval Form
Cardiology **Gastroenterology** **Sleep**	Ablations Cardiac devices Electrophysiology studies Cardiac Catheterization and interventions Sleep studies Oral appliances CPAPS Capsule endoscopy EGDs Hernia repairs **Additional information can be found at Cohere Payer Information Center**	Cohere Health Web: https://login.coherehealth.com Fax: (570) 684-4168 Phone: (855) 482-3649
Diagnostic Radiology/Imaging (Outpatient)	**Imaging** Computed Tomography (CT) Magnetic Resonance Imaging/Angiography (MRI/MRA) Myocardial perfusion (SPECT/PET) and cardiac blood pool imaging Other Nuclear Medicine Position Emission Tomography (PET) **Additional information can be found at Cohere Payer Information Center**.	Cohere Health Web: https://login.coherehealth.com Fax: (570) 684-4168 Phone: (855) 482-3649
Radiation/Oncology Services (outpatient)	**Radiation/Oncology** Brachytherapy Stereotactic Radiation Therapy	EviCore Healthcare Web: https://www.evicore.com/pages/providerlogin.aspx Or

CATEGORY	DETAILS	SUBMIT TO (PROVIDER USE ONLY)
	Intensity Modulated Radiation Therapy (IMRT) Neutron Beam Radiation Therapy Intraoperative Radiation Therapy (IORT) Proton Beam Radiation Therapy Hyperthermia Treatment Radiation Treatment Delivery Radiologic Guidance Therapeutic Radiopharmaceuticals **A full listing by procedure is available at www.evicore.com/resources/healthplan/medical-mutual-of-ohio under Solution Resources.**	Phone: 1-888-693-3211 Fax: 1-866-699-8160.
Home Healthcare Services (All)	**Home Health Care (HHC)** No prior authorization is required for home health care services. The provider is responsible to ensure that home care services are medically necessary to be considered a covered service.	
Inpatient Services	**Medical/Surgical Acute Care Admissions** Acute Care Medical/Surgical Prior approval of normal deliveries is not required unless the length of stay for the mother or child exceeds 48 hours from the date of a vaginal delivery or 96 hours from the date of a C-section.	Medical Mutual contracting providers submit through MedCommunity: https://mmo-prd-pportal.assurecaremc.com/login For all other providers please fax clinical information to 1-800-517-2583
	Medical/Surgical Post-Acute Admissions Acute Physical Rehabilitation Long Term Acute Care (LTAC) Skilled Nursing Facility (SNF)	Medical Mutual contracting providers submit through MedCommunity: https://mmo-prd-pportal.assurecaremc.com/login For all other providers please fax clinical information to 1-800-517-2583
	Behavioral Health Admissions Acute Care Psychiatric/Substance Abuse Residential Inpatient	Medical Mutual contracting providers submit through MedCommunity: https://mmo-prd-pportal.assurecaremc.com/login For all other providers, please fax clinical information to 1-800-524-9817

CATEGORY	DETAILS	SUBMIT TO (PROVIDER USE ONLY)
Therapy	**Therapy** Not all plans require prior approval for therapy services (i.e., Mutual Health Services). Please contact the For Providers number on the back of the Covered Person's ID card. Chiropractic/Osteopathic Manipulative Therapy Occupational Therapy Physical Therapy Speech Therapy **Additional information can be found at Cohere Payer Information Center.**	Cohere Health Web: https://login.coherehealth.com Fax: (570) 684-4168 Phone: (855) 482-3649
Nursing	Private Duty Nursing	Care Management Web: https://login.coherehealth.com **All contracted providers need to submit via the web. Only non-contracted providers can submit via fax.** Fax: 1-877-321-6664 or Prior Approval Form
Transplants	Transplantation – • Blood component (e.g., Stem Cell, Bone Marrow) • Solid Organ (Except Corneal) • Pancreatic Islet Cell - Autologous	Care Management Phone: 1-800-258-3175
Investigational / Experimental Services	The health plan defines investigational procedures, therapies, devices and supplies as services that are not approved by governing bodies OR do not demonstrate comparable or superior outcomes to current practice standards as evidenced by peer-reviewed published literature and/or clinical trials.	Please refer to our Corporate Medical Policies for Investigational/Experimental Services

Commercial and Exchange Prior Authorization List for Medical Drugs

Medical Mutual requires prior approval for the following drugs regardless of whether they are covered under the medical or pharmacy benefits:

- All new specialty drugs
- All new drugs with significant safety, clinical or potential abuse or diversion concerns

This requirement is intended to ensure medications are used safely and will be effective for members. The prior approval criteria for these drugs are detailed in the Global PA/New Drug Prior Approval policy available https://www.medmutual.com/For-Providers/CorporateMedicalDisclaimer.aspx.

Prior authorization for medical drugs should be submitted to Prime Therapeutics (formerly Magellan Rx) at:

Medical Drug Management
Web: www.gatewaypa.com
Fax: 1-888-656-1948
Phone: 1-800-424-7698

Specialty Pharmacy Contact Information

Accredo Health Group
Phone: (866)759-1557
Fax: (888)302-1028
https://www.Accredo.com

Coram Home Infusion
Phone: (866)899-1661
Fax: (866)843-3221
https://www.Coramhc.com

Soleo Health Inc.
Phone: (844)467-8200
Fax: (614)467-8300
https://www.SoleoHealth.com

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
Q2055	Abecma	idecabtagene vicleucel	Oncology			
J9264	Abraxane	paclitaxel protein bound particles	Oncology			
Q5132	Abrilada	adalimumab-afzb	Inflammatory conditions	✓		
J3262	Actemra IV	tocilizumab	BDAID: Rheumatoid arthritis	✓	✓ (A,C,S)	
J3590, C9399	Actemra SQ	tocilizumab	Inflammatory conditions	✓	✓ (A,C,S)	
J0801	Acthar HP	corticotropin	Adrenocorticotropin stimulating hormone	✓		
J0791	Adakveo	crizanlizumab-tmca	Rare disease	✓	✓ (C,S)	
J3590, C9399	Adbry	tralokinumab	Inflammatory conditions	✓		
J9029	Adstiladrin	nadofaragene firadenovec-vncg	Oncology			
J0172	Aduhelm	aducanumab	CNS: Alzheimers			
J3590, C9399	Adzynma	ADAMTS13, recombinant-krhn	Rare disease			
J3590	Ahzantive	Aflibercept-mrbb	Ophthalmic injections			
J3590, C9399	Aimovig	erenumab-aooe	CNS: Migraine	✓		
J3031	Ajovy	fremanezumab-vfrm	CNS: Migraine	✓		

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
J9259	Albumin-Bound Paclitaxel American Regent	albumin-bound paclitaxel	Oncology			
J1931	Aldurazyme	laronidase	Enzyme replacement therapy	✓	✓ (A,C,S)	
J3590, C9399	Alhemo	Concizumab-mtci	Oncology			New PA effective 1/1/2025
J9057	Aliqopa	copanlisib	Oncology			
Q5126	Alymsys	bevacizumab-maly	Oncology			
J1426	Amondys 45	casimersen	Rare disease	✓		
J9999	Amtagvi	Lifileucel	Oncology			
J0225	Amvuttra	vutrisiran	Rare disease		✓ (A,S)	
J3490, C9399	Anktiva	Nogapendekin alfa inbakicept-pmln	Oncology			
J3490, C9399	Aphexda	motixafortide	Hematopoetic stem cell mobilizer			
J0256	Aralast NP	alpha-1-proteinase inhibitor	Alpha-1 Proteinase Inhibitor	✓	✓ (A,C)	
J0881	Aranesp	darbepoetin alfa	Erythropoiesis stimulating agents			
J2793	Arcalyst	rilonacept	BDAID: Rare autoinflammatory conditions			
J9261	Arranon	nelarabine	Oncology			
J9302	Arzerra	ofatumumab	Oncology			
J1554	Asceniv	intravenous Immune globULin	Immune globulin	✓	✓ (A,C,S)	
J9118	Asparlas	calaspargase pegol-mknl	Oncology			
C9399, J9999	Aucatzyl	Obecabtagene autoleucel	Oncology			
J9035	Avastin	bevacizumab	Inflammatory conditions		✓ (A,C,S)	
J3145	Aveed	Testosterone undecanoate	Testosterone			
J1826, Q3027	Avonex	interferon beta-1a	Multiple sclerosis	✓	✓ (A,S)	
Q5121	Avsola	infliximab-axxq	Inflammatory conditions	✓	✓ (A,C,S)	
J9999, C9399	Avzivi	bevacizumab-tnjn	Inflammatory conditions			

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
A9590	Azedra	iobenguane I-131	Oncology			
J9023	Bavencio	avelumab	Oncology			
J9036	Belrapzo	bendamustine ready-to-dilute	Oncology		✓ (A)	
J9058	bendamustine Apotex	bendamustine hydrochloride	Oncology			
J9059	bendamustine Baxter	bendamustine hydrochloride	Oncology			
J9034	Bendeka	bendamustine hcl	Oncology			
J0490	Benlysta IV	belimumab	BDAID: Systemic lupus erythematosus	✓	✓ (A,C,S)	
J3590	Benlysta SQ	belimumab	Autoimmune condition	✓	✓ (A,S)	
J0179	Beovu	brolucizumab-dbll	Ophthalmic injections		✓ (A)	
J0597	Berinert	C-1 esterase inhibitor human	Hereditary angioedema	✓	✓ (A,C)	
J9229	Besponsa	inotuzumab ozogamicin	Oncology		✓ (A,C)	
J9999, C9399	Besremi	ropeginterferon alfa-2b-njft	Oncology			
J1830	Betaseron	interferon beta-1b	Multiple sclerosis	✓	✓ (A,S)	
J1556	Bivigam	intravenous Immune globULin	Immune globulin	✓	✓ (A,C,S)	
J1300	Bkemv	eculizumab-aeeb	Rare disease	✓		
J9037	Blenrep	belantamab mafodotin-blmf	Oncology			
J9039	Blincyto	blinatumomab	Oncology			
J0585	Botox	OnabotulinumtoxinA	Botulinum toxins			
Q2054	Breyanzi	lisocabtagene maraleucel	Oncology			
J0567	Brineura	cerliponase alfa	Rare disease			
J2329	Briumvi	Ublituximab	Multiple sclerosis	✓		
Q5124	Byooviz	ranibizumab-nuna	Ophthalmic injections			
J9064	cabazitaxel (sandoz)	cabazitaxel	Oncology			
J0741	Cabenuva	cabotegravir and rilpivirine	Human immunodeficiency virus	✓	✓ (A,S)	
C9047, J3590	Cablivi	caplacizumab-yhdp	Rare disease			

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
Q2056	Carvykti	ciltacabtagene autoleucel	Oncology			
J3590, C9399	Casgevy	exagamglogene autotemcel	Rare disease			
J1786	Cerezyme	imiglucerase	Enzyme replacement therapy	✓	✓ (A,C,S)	
Q5128	Cimerli	ranibizumab-eqrn	Ophthalmic injections			
J0717	Cimzia	certolizumab pegol	Inflammatory conditions	✓	✓ (A,C,S)	
J2786	Cinqair	reslizumab	Respiratory		✓ (C,S)	
J0598	Cinryze	C1 esterase inhibitor	Hereditary angioedema	✓	✓ (A)	
J9286	Columvi	glofitamab-gxbm	Oncology			
J1595	Copaxone	glatiramer acetate	Multiple sclerosis		✓ (A,S)	
J0802	Cortrophin Gel	repository corticotropin injection	Adrenocorticotropin stimulating hormone	✓		
J1448	Cosela	trilaciclib	ONC support			
C9399, J3590	Cosentyx SQ	secukinumab	Inflammatory conditions	✓		
J3590, C9399	Cosentyx IV	secukinumab	Inflammatory conditions	✓		
J0584	Crysvita	burosumab-twza	Enzyme replacement therapy	✓	✓ (A,C,S)	
J1551	Cutaquig	subcutaneous Immune globULin	Immune globulin	✓	✓ (A,C,S)	
J1555	Cuvitru	subcutaneous Immune globULin	Immune globulin	✓	✓ (A,C,S)	
J9308	Cyramza	ramucirumab	Oncology		✓ (A)	
J9348	Danyelza	naxitamab-gqgk	Oncology			
J9145	Darzalex	daratumumab	Oncology			
J9144	Darzalex Faspro	daratumumab; hyaluronidase-fihj	Oncology			
J9999, C9399	Datroway	datopotamab deruxtecan-dlnk	Oncology			New PA effective 1/1/2025
J3590, C9160	Daxxify	daxibotulinumtoxinA-lanm	Botulinum toxins			
J3121	Delatestryl	Testosterone enanthate	Testosterone			
J1071	Depo-Testosterone	Testosterone cypionate	Testosterone			

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
J3590, C9399	Dupixent	dupilumab	Inflammatory conditions	✓		
J7318	Durolane	hyaluronan or derivative	Viscosupplementation			
J0586	Dysport	abobotulinumtoxinA	Botulinum toxins			
J3590, C9399	Ebglyss	Lebrikizumab	Atopic Dematitis			
J9063	Elahere	mirvetuximab soravtansine	Oncology			
J1743	Elaprase	idursulfase	Enzyme replacement therapy	✓	✓ (A,C,S)	
J3060	Elelyso	taliglucerase alfa	Enzyme replacement therapy	✓	✓ (A,C)	
J3590, C9399	Elevidys	Delandistrogene moxeparvovec	Rare disease			
J2508	Elfabrio	pegunigalisidase alfa-iwxj	Enzyme replacement therapy	✓		
J9999, C9165	Elrexfio	elranatamab-bcmm	Oncology			
J9269	Elzonris	tagrazofusp-erzs	Oncology			
J3590, C9399	Emgality	galcanezumab-gnlm	Rare disease	✓		
J3490, C9399, J7799	Empaveli	pegcetacoplan	Rare disease	✓		
J9176	Empliciti	elotuzumab	Oncology		✓ (A)	
C9399, J3590	Encelto	Revakinagene taroretcel-lwey	Ocular Rare disease			New PA effective 3/1/2025
J1438	Enbrel	etanercept	Inflammatory conditions	✓		
J9358	Enhertu	fam-trastuzumab deruxtecan-nxki	Oncology		✓ (A)	
J1302	Enjaymo	sutimlimab-jome	Hematology			
J3590, C9399	Enspryng	satralizumab	Rare disease	✓		
J3380	Entyvio	vedolizumab	BDAID: Chrons disease/ulcerative colitis	✓	✓ (A,C,S)	
J3590, C9399	Entyvio SQ	vedolizumab	Inflammatory conditions	✓	✓ (A,C)	
J9321	Epkinly	epcoritamab-bysp	Oncology			
J0885	Epogen	epoetin alfa	Erythropoiesis stimulating agents			
J9055	Erbitux	cetuximab	Oncology		✓ (A,C)	

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
J7323	Euflexxa	hyaluronan or derivative	Viscosupplementation			
J3111	Evenity	romosozumab-aqqg	Osteroporosis	✓	✓ (A,C,S)	
J1305	Evkeeza	evinacumab-dgnb	Rare disease	✓		
J1428	Exondys 51	eteplirsen	Rare disease	✓		
J1830	Extavia	interferon beta-1b	Multiple sclerosis	✓	✓ (S)	
J0178	Eylea	aflibercept	Ophthalmic injections		✓ (A)	
J3590, C9161	Eylea HD	aflibercept	Ophthalmic injections			
J0180	Fabrazyme	agalsidase beta	Enzyme replacement therapy	✓	✓ (A,C,S)	
J0517	Fasenra IV	benralizumab	Respiratory	✓	✓ (S)	
J1744	Firazyr	icatibant	Hereditary angioedema	✓		
J1572	Flebogamma	intravenous Immune globULin	Immune globulin	✓		
J1325	Flolan	epoprostenol	Pulmonary arterial hypertension	✓		
Q5108	Fulphila	pegfilgrastim-jmdb	Colony stimulating factors			
J0641	Fusilev	levoleucovorin	Oncology			
J9331	Fyarro	sirolimus albumin-bound nanoparticles	Oncology			
Q5130	Fylnetra	pegfilgrastim-pbbk	Colony stimulating factors			
J9210	Gamifant	emapalumab-lzsg	Rare disease		✓ (C)	
J1569	Gammagard Liquid	intravenous Immune globULin	Immune globulin	✓	✓ (A,C,S)	
J1566	Gammagard S/D	intravenous Immune globULin	Immune globulin	✓	✓ (A,C,S)	
J1561	Gammaked	intravenous Immune globULin	Immune globulin	✓	✓ (A,C,S)	
J1557	Gammaplex	intravenous Immune globULin	Immune globulin	✓	✓ (A,S,C)	
J1561	Gamunex-C	intravenous Immune globULin	Immune globulin	✓	✓ (A,S,C)	
J9301	Gazyva	obinutuzumab	Oncology		✓ (A,C)	
J7326	Gel-One	hyaluronan or derivative	Viscosupplementation			
J7328	Gel-Syn	hyaluronan or derivative	Viscosupplementation			

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
J2941	Genotropin	somatropin	Growth hormone	✓	✓ (A,C,S)	
J7320	GenVisc 850	hyaluronan or derivative	Viscosupplementation			
J0223	Givlaari	givosiran	Rare disease	✓	✓ (A,S)	
J0257	Glassia	alpha-1-proteinase inhibitor	Alpha-1 Proteinase Inhibitor	✓	✓ (A,C)	
J1595	Glatopa	glatiramer acetate	Multiple sclerosis			
J1447	Granix	tbo-filgrastim	Colony stimulating factors			
J0599	Haegarda	c-1 esterase inhibitor (human)	Hereditary angioedema	✓		
J1411	Hemgenix	etranacogene dezaparvovec-drlb	Antihemophilics			
J7170	Hemlibra	emicizumab-kxwh	Antihemophilics	✓	✓ (A,C,S)	
J9355	Herceptin	trastuzumab	Oncology			
J9356	Herceptin-Hylecta	trastuzumab and hyaluronidase-oysk	Oncology			
Q5113	Herzuma	trastuzumab-pkrb	Oncology			
J1559	Hizentra	subcutaneous Immune globULin	Immune globulin	✓	✓ (A,C,S)	
J2941	Humatrope	somatropin	Growth hormone	✓	✓ (A,C)	
J0135	Humira	adalimumab	Inflammatory conditions	✓	✓ (A,S)	
J7321	Hyalgan	Hyaluronan or derivative, hyalgan or supartz, for intra-articular injection, per dose	Viscosupplementation			
C9399, J3590	Hympavzi	Marstacimab-hncq	Antihemophilics			
J7322	Hymovis	hyaluronan or derivative	Viscosupplementation			
J1575	HyQvia	subcutaneous Immune globULin	Immune globulin	✓	✓ (A,C,S)	
Q5131	Idacio	adalimumab-aacf	Inflammatory conditions	✓		
J0638	Ilaris	canakinumab	BDAID: Rare	✓	✓ (A,S)	

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
			autoinflammatory conditions			
J3245	Ilumya	tildrakizumab-asmn	BDAID: Psoriasis/psoriatic arthritis	✓	✓ (A,S)	
J3490, C9399	Imcivree	setmelanotide	Weight management			
C9170	Imdeltra	tarlatamab	Oncology			
J9173	Imfinzi	durvalumab	Oncology		✓ (A)	
J9347	Imjudo	tremelimumab-actl	Oncology		✓ (A)	
J9325	Imlygic "T-Vec"	talimogene laherparepvec	Oncology			
J2170	Increlex	mecasermin	Growth hormone	✓	✓ (A)	
Q5103	Inflectra	infliximab-dyyb	Inflammatory conditions	✓	✓ (A,C,S)	
J9198	Infugem	gemcitabine	Oncology			
J9319	Istodax	romidepsin	Oncology			
J9207	Ixempra	ixabepilone	Oncology		✓ (A)	
J3490, C9162	Izervay	avacincaptad pegol	Ophthalmic injections			
J9281, C9064	Jelmyto	mitomycin	Oncology			
J9272	Jemperli	dostarlimab-gxly	Oncology		✓ (A,C)	
J9043	Jevtana	cabazitaxel	Oncology		✓ (A)	
J9354	Kadcyla	ado-trastuzumab emtansine	Oncology			
J1290	Kalbitor	ecallantide	Hereditary angioedema	✓	✓ (A,C,S)	
Q5117	Kanjinti	trastuzumab-anns	Oncology			
J2840	Kanuma	sebelipase alfa	Enzyme replacement therapy	✓	✓ (A,C,S)	
J3590	Kebilidi	Eladocagene Exuparvovec	Rare Disease (Enzyme Deficiency)			Not covered effective 11/1/2024
J3590, C9399	Kesimpta	ofatumumab	Oncology	✓		
J3590, C9399	Kevzara	sarilumab	Inflammatory conditions	✓		
J9271	Keytruda	pembrolizumab	Oncology		✓ (C)	
J0642	Khapzory	levoleucovorin	Oncology			

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
J9274	Kimmtrak	tebentafusp-tebn	Oncology			
J3590	Kineret	anakinra	Inflammatory conditions	✓		
J0175	Kisunla	Donanemab-azbt	Alzheimer disease			
J2507	Krystexxa	pegloticase	Gout	✓	✓ (A,C,S)	
Q2042	Kymriah	tisagenlecleucel	Oncology			
J9047	Kyprolis	carfilzomib	Oncology		✓ (A)	
J0217	Lamzede	velmanase alfa-tycv	Rare disease	✓		
J3590, C9399	Lenmeldy	Atidarsagene Autotemcel	Rare disease			
J0202	Lemtrada	alemtuzumab	Oncology	✓	✓ (A,C)	
J3590, C9399	Leqembi	lecanemab-irmb	Alzheimer disease			
J1306	Leqvio	inclisiran	Cardiovascular agent	✓	✓ (S)	
J2820	Leukine	sargramostim	Colony stimulating factors		✓ (A,C,S)	
J9119	Libtayo	cemiplimab-rwlc	Oncology			
J9999, C9399	Loqtorzi	toripalimab-tpzi	Oncology			
J2778	Lucentis	ranibizumab	Ophthalmic injections		✓ (A)	
J0221	Lumizyme	alglucosidase alfa	Enzyme replacement therapy	✓	✓ (A,C,S)	
J9313	Lumoxiti	moxetumomab pasudotox-tdfk	Oncology			
J9350	Lunsumio	mosunetuzumab-axgb	Oncology			
J1950	Lupron Depot 3.75	leuprolide acetate depot	Gonadotropin releasing hormone agonist		✓ (A,C,S)	
J9217	Lupron Depot 7.5	leuprolide acetate depot	Oncology		✓ (A,C)	
A9513	Lutathera	lutetium Lu 177 dotatate	Oncology			
J3398	Luxturna	voretigene neparvovec-rzyl	Rare disease			
J3590, C9399	Lyfgenia	lovotibeglogene autotemcel	Rare disease			
J9999	Lymphir	Denileukin diftitox-cxdl	Oncology			
J9353	Margenza	margetuximab-cmkb	Oncology			

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
J3397	Mepsevii	vestronidase alfa-vjbk	Enzyme replacement therapy	✓	✓ (A)	
J0888	Mircera	epoetin beta	Erythropoiesis stimulating agents			
J9349	Monjuvi	tafasitamab-cxix	Oncology			
J7327	Monovisc	hyaluronan or derivative	Viscosupplementation			
Q5107	Mvasi	bevacizumab-awwb	Inflammatory conditions			
J9203	Mylotarg	gemtuzumab ozogamicin	Oncology		✓ (A)	
J0587	Myobloc	rimabotulinumtoxinB	Botulinum toxins			
J1458	Naglazyme	galsulfase	Enzyme replacement therapy	✓	✓ (A,C)	
J2506	Neulasta	pegfilgrastim	Colony stimulating factors			
J1442	Neupogen	filgrastim	Colony stimulating factors		✓ (A,C,S)	
J0219	Nexviazyme	avalglucosidase alfa-ngpt	Rare disease	✓		
J3590, C9399	Ngenla	somatrogon-ghla	Growth hormone	✓		
J3590	Niktimvo	Axatilimab-csfr	Graft-versus-host disease			
Q5110	Nivestym	filgrastim-aafi	Colony stimulating factors			
J2941	Norditropin	somatropin	Growth hormone	✓	✓ (A,C,S)	
J2796	Nplate	romiplostim	Hematology		✓ (A,C,S)	
J2182	Nucala	mepolizumab	Respiratory	✓	✓ (A,C,S)	
J3490, C9399	Nulibry	fosdenopterin	Rare disease			
J3590	Nypozi	filgrastim-txid	Colony stimulating factors			
Q5122	Nyvepria	pegfilgrastim-apgf	Colony stimulating factors			
J2350	Ocrevus	ocrelizumab	Multiple sclerosis	✓	✓ (A,C,S)	
C9399, J3590	Ocrevus Zenovo	Ocrelizumab and hyaluronidase	Multiple sclerosis			
J1568	Octagam	intravenous Immune globULin	Immune globulin	✓	✓ (A,C,S)	
Q5114	Ogivri	trastuzumab-dkst	Oncology			
C9399, J3590	Omlyclo	omalizumab-igec	Respiratory	✓		New PA requirement

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
						effective 5/1/2025
J2941	Omnitrope	somatropin	Growth hormone	✓	✓ (A)	
J3590, C9399	Omvoh IV	mirikizumab-mrkz	Inflammatory conditions			
C9399, J3490	Onapgo	Apomorphine hydrochloride	Parkinson Disease			New PA effective 3/1/2025
J9205	Onivyde	irinotecan liposome	Oncology			
J0222	Onpattro	patisiran lipid complex	Rare disease		✓ (A,C,S)	
Q5112	Ontruzant	trastuzumab-dttb	Oncology			
J9299	Opdivo	nivolumab	Oncology		✓ (A)	
J9298	Opdualag	nivolumab and relatlimab-rmbw	Oncology			
J0129	Orencia IV	abatacept	BDAID: Rheumatoid arthritis	✓	✓ (A,C,S)	
J0129	Orencia SQ	abatacept	BDAID: Rheumatoid arthritis	✓	✓ (A,C,S)	
J7324	Orthovisc	hyaluronan or derivative	Viscosupplementation			
J0224	Oxlumo	lumasiran	Rare disease		✓ (S)	
J9258	paclitaxel-albumin bound Teva	paclitaxel-albumin bound	Oncology			
J9177	Padcev	enfortumab vedotin-ejfv	Oncology			
J3590, C9399	Palynziq	pegvaliase-pqpz	Rare disease	✓		
J1640	Panhematin	hemin	Hematology			
J1576	Panzyga	intravenous Immune globULin	Immune globulin	✓		
J0208	Pedmark	sodium thiosulfate	ONC support			
J9304	Pemfexy	pemetrexed	Oncology			
J9306	Perjeta	pertuzumab	Oncology		✓ (A,C)	
J9316	Phesgo	pertuzumab; trastuzumab; hyaluronidase-zzxf	Oncology		✓ (A,C)	
C9399, J3590	Piasky	Crovalimab-akkz	Rare disease			

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
C9399, J3590	Plegridy	peginterferon beta-1a	Rare disease	✓		
A9607	Pluvicto	lutetium (177LU) vipivotide tetraxetan	Oncology			
J9309	Polivy	polatuzumab vedotin-piiq	Oncology		✓ (A)	
J3590, C9399	Pombiliti	cipaglucosidase alfa-atga	Multiple Sclerosis			
J9295	Portrazza	necitumumab	Oncology		✓ (A)	
J9204	Poteligio	mogamulizumab-kpkc	Oncology			
J3490, C9399	Praluent	alirocumab	Cardiovascular agent			
J1459	Privigen	intravenous Immune globULin	Immune globulin	✓	✓ (A,C,S)	
J0885	Procrit	epoetin alfa	Erythropoiesis stimulating agents			
J0256	Prolastin-C	alpha-1-proteinase inhibitor	Alpha-1 Proteinase Inhibitor	✓		
Q2043	Provenge	sipuleucel-t	Oncology			
J3590	Pyzchiva	Ustekinumab-ttwe	Inflammatory conditions	✓		
J1304	Qalsody	tofersen	CNS: Rare diseases			
J1301	Radicava	edaravone	CNS: Rare diseases	✓	✓ (A,C,S)	
Q3028	Rebif	interferon beta-1a	Multiple sclerosis	✓		
J0896	Reblozyl	luspatercept-aamt	Rare disease			
Q5125	Releuko	filgrastim-ayow	Colony stimulating factors			
J1745	Remicade	infliximab	Inflammatory conditions	✓	✓ (A,C,S)	
J3285	Remodulin	treprostinil	Pulmonary arterial hypertension	✓		
Q5104	Renflexis	infliximab-abda	Inflammatory conditions	✓	✓ (A,C,S)	
C9399, J3490	Repatha	evolocumab	Cardiovascular agent			
Q5106	Retacrit	epoetin alfa-epbx	Erythropoiesis stimulating agents			
J3590, C9399	Revcovi	elapegademase-lvlr	Rare disease			
Q5123	Riabni	rituximab-arrx	Oncology			

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
J9312	Rituxan	rituximab	Oncology			
J9311	Rituxan Hycela	rituximab and hyaluronidase human	Oncology			
J3490, C9399	Rivfloza	nedosiran	Rare disease			
J1412	Roctavian	valoctocogene roxaparvovec-rvox	Antihemophilics			
J1449	Rolvedon	eflapegrastim-xnst	Colony stimulating factors			
J9318	Romidepsin	romidepsin non-lyophilized (e.g. liquid)	Oncology			
J0596	Ruconest	c1 esterase inhibitor [recombinant]	Hereditary angioedema	✓	✓ (A)	
Q5119	Ruxience	rituximab-pvvr	Oncology			
J9061	Rybrevant	amivantamab-vmjw	Oncology			
J9021	Rylaze	asparaginase erwinia chrysanthemi (recombinant)-rywn	Oncology			
J3590	Ryoncil	Remestemcel-L	Graft versus host disease			New PA effective 1/1/2025
J2998	Ryplazim	plasminogen, human-tvmh	Rare disease			
J9333	Rystiggo	rozanolixizumab-noli	Hematology: MG			
J9999, C9399	Rytelo	Imetelstat	Oncology			
J9361	Ryzneuta	Efbemalenograstim Alfa	Colony stimulating factors			
J2941	Saizen	somatropin	Growth hormone	✓		
J0491	Saphnelo	anifrolumab-fnia	BDAID: Systemic lupus erythematosus	✓		
J9227	Sarclisa	Isatuximab-irfc	Oncology			
J7352	Scenesse	afamelanotide	Rare disease			
J2941	Serostim	somatropin	Growth hormone	✓		
J3590, C9399	Siliq	brodalumab	Inflammatory conditions	✓		
J1602	Simponi Aria IV	golimumab	Inflammatory conditions	✓	✓ (A,C,S)	

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
J3590, C9399	Simponi SQ	golimumab	Inflammatory conditions	✓	✓ (A,C,S)	
J2327	Skyrizi IV	risankizumab-rzaa	BDAID: Chrons disease/ulcerative colitis	✓	✓ (A,C,S)	
J3590, C9399	Skyrizi SQ	risankizumab-rzaa	Inflammatory conditions	✓	✓ (A,S)	
J3590, C9399	Skysona	Elivaldogene autotemcel	Rare disease			
J3590, C9399	Skytrofa	lonapegsomatropin-tcgd	Growth hormone	✓		
J3590, C9399	Sogroya	somatropin	Growth hormone	✓		
J1300	Soliris	eculizumab	Rare disease	✓	✓ (A,C,S)	
J1747	Spevigo	spesolimab	BDAID: Psoriasis/psoriatic arthritis		✓ (A,S)	
J2326	Spinraza	nusinersen	CNS: Rare diseases			
S0013, G2082, G2083	Spravato	esketamine	Psychotherapeutic			
J3358	Stelara IV	ustekinumab	BDAID: Chrons disease/ulcerative colitis	✓	✓ (A,C,S)	
J3357	Stelara SQ	ustekinumab	Inflammatory conditions	✓	✓ (A,C,S)	
Q5127	Stimufend	pegfilgrastim-fpgk	Colony stimulating factors			
J7321	Supartz FX	Hyaluronan or derivative, hyalgan or supartz, for intra-articular injection, per dose	Viscosupplementation			
J2779	Susvimo	ranibizumab	Ophthalmic injections			
J2781	Syfovre	pegcetacoplan	Ophthalmic injections			
J2860	Sylvant	siltuximab	Oncology		✓ (A,C)	
90378	Synagis	palivizumab	Vaccine			
J9262	Synribo	omacetaxine	Oncology			
J7325	Synvisc, Synvisc-One	hyaluronan or derivative	Viscosupplementation			
J0593	Takhzyro	lanadelumab-flyo	Hereditary angioedema	✓	✓ (A)	

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
J3590, C9399	Taltz	ixekizumab	Inflammatory conditions			
J9999, C9163	Talvey	talquetamab-tgvs	Oncology			
Q2053	Tecartus	brexucabtagene autoleucel	Oncology			
J9999, C9399	Tecelra	Afamitresgene Autoleucel	Oncology			
J9022	Tecentriq	atezolizumab	Oncology		✓ (A,C)	
C9399, J9999	Tecentriq Hybreza	Atezolizumab and hyaluronidase	Oncology			
J9380	Tecvayli	teclistamab-cqyv	Oncology			
J3490, C9399	Tegsedi	inotersen	Rare disease	✓		
J3241	Tepezza	teprotumumab-trbw	Rare disease	✓	✓ (A,C,S)	
J3490, C9399, S0189	Testopel	Testosterone pellets	Testosterone			
J9329	Tevimbra	Tislelizumab	Oncology			
J2356	Tezspire	tezepelumab-ekko	Respiratory	✓	✓ (A,S)	
J9273	Tivdak	tisotumab vedotin-tftv	Oncology		✓ (A,C)	
J3590, C9399	Tofidence	tocilizumab-bavi	Inflammatory conditions	✓		
Q5116	Trazimera	trastuzumab-qyyp	Oncology			
J9033	Treanda	bendamustine	Oncology			
J1628	Tremfya	guselkumab	BDAID: Psoriasis/psoriatic arthritis	✓	✓ (A,C,S)	
J3590	Tremfya IV	guselkumab	Inflammatory conditions			
J7332	Triluron	hyaluronan or derivative	Viscosupplementation			
J7329	Trivisc	hyaluronan or derivative	Viscosupplementation			
J9317	Trodelvy	sacituzumab govitecan-hziy	Oncology			
J1746	Trogarzo	ibalizumab-uiyk	Human immunodeficiency virus	✓	✓ (A,C)	
Q5115	Truxima	rituximab-abbs	Inflammatory conditions			
Q5135	Tyenne IV	Tocilizumab-aazg	Inflammatory conditions			
Q5135	Tyenne SC	Tocilizumab-aazg	Inflammatory conditions			

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
J3590, C9399	Tyruko	natalizumab-sztn	Multiple Sclerosis	✓		
J2323	Tysabri	natalizumab	Multiple Sclerosis	✓	✓ (A,C,S)	
J7686	Tyvaso	treprostinil	Pulmonary arterial hypertension	✓		
J9381	Tzield	teplizumab-mzwv	Diabetes			
Q5111	Udenyca	pegfilgrastim-cbqv	Colony stimulating factors			
J1303	Ultomiris	ravulizumab-cwvz	Rare disease	✓	✓ (A,C,S)	
J9999	Unloxcyt	Cosibelimab	Oncology			New PA effective 1/1/2025
J1823	Uplizna	inebilizumab-cdon	Hematology: NMOSD			
J2777	Vabysmo	faricimab-svoa	Ophthalmic injections		✓ (A)	
J9303	Vectibix	panitumumab	Oncology		✓ (A)	
Q5129	Vegzelma	bevacizumab-adcd	Oncology			
J1325	Veletri	epoprostenol	Pulmonary arterial hypertension	✓		
Q4074	Ventavis	iloprost	Pulmonary arterial hypertension	✓		
J3590, C9399	Veopoz	pozelimab-bbfg	Rare disease			
J1427	Viltepso	viltolarsen	Rare disease	✓	✓ (S)	
J1322	Vimizim	elosulfase alfa	Enzyme replacement therapy	✓	✓ (A,C)	
J7321	Visco-3	hyaluronan or derivative	Viscosupplementation			
J3396	Visudyne	verteporfin	Ophthalmic injections		✓ (A)	
J9056	Vivimusta	bendamustine hydrochloride injection	Oncology			
J3590, C9399	Voxzogo	vosoritide	Rare disease	✓		
J3385	Vpriv	velaglucerase alfa	Enzyme replacement therapy	✓	✓ (A,C,S)	
J7799, C9399	Vyalev	Foscarbidopa and foslevodopa	Parkinson Disease			New PA effective 3/1/2025
J3032	Vyepti	eptinezumab-jjmr	CNS: Migraine	✓	✓ (S)	

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
J3401	Vyjuvek	beremagene geperpavec-svdt	Rare disease			
J3490	Vyleesi	bremelanotide	Hypoactive sexual desire disorder			
J3590, C9399	Vyloy	Zolbetuximab-clzb	Oncology			
J1429	Vyondys 53	golodirsen	CNS: Rare diseases	✓		
J9332	Vyvgart	efgartigimod alfa	Hematology: MG		✓ (A,C,S)	
J9334	Vyvgart Hytrulo	efgartigimod alfa hyaluronidase-qvfc	Hematology: MG	✓		
J9153	Vyxeos	daunorubibin/cytarabine	Oncology			
J3940	Wainua	eplontersen	Rare disease			
J3590, C9399	Winrevair	Sotatercept	Pulmonary arterial hypertension			
J1558	Xembify	subcutaneous Immune globULin	Immune globulin	✓	✓ (A,C,S)	
J0218	Xenpozyme	olipudase alfa	Rare disease			
J0588	Xeomin	incobotulinumtoxinA	Botulinum toxins			
J2357	Xolair	omalizumab	Respiratory	✓	✓ (A,C,S)	
J3490, C9399	Xyosted	Testosterone enanthate	Testosterone			
J9228	Yervoy	ipilimumab	Oncology		✓ (A,C)	
Q2041	Yescarta	axicabtagene ciloleucel	Oncology			
J9352	Yondelis	trabectedin	Oncology		✓ (C)	
J9400	Zaltrap	ziv-aflibercept	Oncology		✓ (A)	
Q5101	Zarxio	filgrastim-sndz	Colony stimulating factors			
J0256	Zemaira	alpha-1-proteinase inhibitor	Alpha-1 Proteinase Inhibitor	✓	✓ (A,C)	
J9223	Zepzelca	lurbinectedin	Oncology			
Q5120	Ziextenzo	pegfilgrastim-bmez	Colony stimulating factors			
J3490, C9399	Zilbrysq	zilucoplan	Rare disease			
J3304	Zilretta	triamcinolone acetonide ER	Corticosteroids			

HCPCS	Brand Name	Generic Name	Drug Category	Subject to Site of Care*	Subject to Medication Sourcing Starting 1/1/2025 A = Accredo S = Soleo C = Coram	New Prior Authorization Requirement - Within last 90 days of Revised List
Q5118	Zirabev	bevacizumab-bvzr	Inflammatory conditions		✓ (A,C)	
J3399	Zolgensma	onasemnogene abeparvovec-xioi	CNS: Rare diseases			
J2941	Zomacton	somatropin	Growth hormone	✓		
J2941	Zorbtive	somatropin	Growth hormone	✓		
J9359	Zynlonta	loncastuximab tesirine-lpyl	Oncology			
J3590, C9399	Zynteglo	betibeglogene autotemcel	Hematology			
J9345	Zynyz	retifanlimab-dlwr	Oncology			

*Drugs require administration at home, provider office or ambulatory infusion center.